Findings from the BEAT‐ROP trial (Mintz‐Hittner et al., 2011), which demonstrated a benefit of bevacizumab over laser therapy in Zone I but not in Zone II disease, may have led clinicians to preferentially use anti‐VEGF therapy for more severe ROP or less mature infants. This evidence concerns the gene VEGFA and retinopathy of prematurity.